SM
SAGE

SG3 Management’s Sage Therapeutics SAGE Stock Holding History

SG3 Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,000
Closed -$517K – 415
2022
Q2 		$517K Buy
16,000
+11,000
+220% +$369K 0.06% 205
2022
Q1 		$166K Sell
5,000
-37,500
-88% -$1.41M ﹤0.01% 787
2021
Q4 		$1.81M Buy
42,500
+6,000
+16% +$251K 0.04% 360
2021
Q3 		$1.62M Buy
+36,500
New +$1.67M 0.05% 350

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG3 Management's SAGE Position: Q3 2022 in Review

SG3 Management sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 16,000 shares — an estimated $517K sold.

SG3 Management first reported a position in SAGE in Q3 2021 and held it in 4 quarters. The position peaked at $1.81M in Q4 2021. 201 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • SG3 Management reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
  • SG3 Management sold 16,000 Sage Therapeutics shares in Q3 2022, an estimated $517K.
  • SG3 Management first reported a position in Sage Therapeutics in Q3 2021 and held it in 4 quarters.
  • SG3 Management's Sage Therapeutics position peaked at $1.81M in Q4 2021.
  • 201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.